Osteoporosis Drug Information

Empagliflozin’s cardiovascular benefits lead the change in T2D treatment paradigm

11 May 2020

This second issue revisits the impact EMPA-REG OUTCOME had on clinical practice and helps readers discover how it gives life back to patients through its cardiovascular indication. Learn how it was approved and the possible mechanisms for its cardiovascular benefits.

EMPA-REG OUTCOME: A breakthrough trial in type 2 diabetes

08 Apr 2020

This is the first issue in a series of five articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data release. This issue brings insight to the trial’s background, study design and key results.

Empagliflozin’s clinical endorsement: Revolutionising guidelines across specialties

08 Jun 2020

In this third issue we take a look at how empagliflozin made a bold impact on clinical guidelines across multiple specialties. We will explore how existing treatment recommendations were altered, and summarise the current guidelines and future perspectives of empagliflozin’s use.